GMAB
Genmab A/SBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Genmab is still growing on the back of DARZALEX/Kesimpta royalties and EPKINLY sales, while the late-stage Rina-S and petosemtamab programs plus ASCO/EHA visibility keep multiple shots on goal alive.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Concentration risk remains high because current growth is still heavily reliant on DARZALEX and Kesimpta royalties plus EPKINLY uptake.
Momentum
46
Value
65
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $36.86 · Bull $44.00 · Bear $21.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $37.13
Why
Momentum46 · Δ7d -3.5
Value65 · Δ7d -0.1
Sentiment64 · Δ7d -3.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
46
26% active weight
Current posture
7d trendSoftening
Δ7d
-3.5
Δ21d
+15.6
Value
65
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+3.2
Sentiment
64
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.0
Δ21d
-13.3
Why this grade
Composite grade B. Momentum 45.5 / Value 64.9 / Sentiment 63.6
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$17.15B
Beta
0.76
Shares Out
594.94M
P/E (TTM)
13.4
P/S (TTM)
5.65
P/FCF (TTM)
16.83
Rev YoY
+25.7%
EPS YoY
-71.8%
Gross Margin
+93.3%
Op Margin
+36.7%
Net Debt
$3.71B
Current Ratio
2.18
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology